摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-tert-butyl-3-chloro-2-methoxy-phenylamine | 33353-66-1

中文名称
——
中文别名
——
英文名称
5-tert-butyl-3-chloro-2-methoxy-phenylamine
英文别名
5-tert-butyl-3-chloro-2-methoxyaniline
5-tert-butyl-3-chloro-2-methoxy-phenylamine化学式
CAS
33353-66-1
化学式
C11H16ClNO
mdl
——
分子量
213.707
InChiKey
MSOMCVWHDFNQGU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-tert-butyl-3-chloro-2-methoxy-phenylaminelead dioxide 作用下, 生成 3.3'-Dichloro-2.2'-dimethoxy-5.5'-di-tert.butylazobenzol
    参考文献:
    名称:
    Oxidation of ethers of derivatives of o-aminophenol by lead dioxide
    摘要:
    DOI:
    10.1007/bf00855362
  • 作为产物:
    描述:
    6-Chloro-2-nitro-4-tert-butylphenol-methylaether氯化亚锡二水合物乙醚magnesium sulfate乙酸乙酯 作用下, 以 盐酸 为溶剂, 反应 2.0h, 以to yield 100 mg of final product的产率得到5-tert-butyl-3-chloro-2-methoxy-phenylamine
    参考文献:
    名称:
    CYTOKINE INHIBITORS
    摘要:
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别地,本发明的化合物可用作抗炎剂。还提供了制备这种剂和在预防或治疗由细胞因子介导的疾病,如关节炎中使用这种剂的方法。
    公开号:
    US20100093735A1
点击查看最新优质反应信息

文献信息

  • CYTOKINE INHIBITORS
    申请人:Boman Erik
    公开号:US20100093734A1
    公开(公告)日:2010-04-15
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别是,本发明的化合物可用作抗炎剂。还提供了制备这种药剂的方法,以及其在预防或治疗由细胞因子介导的疾病,如关节炎方面的用途。
  • Alpha-ketoamides and derivatives thereof
    申请人:Itherx Pharmaceuticals, Inc.
    公开号:US07749999B2
    公开(公告)日:2010-07-06
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别地,本发明的化合物可用作抗炎剂。还提供了制备此类药剂的方法,并用于预防或治疗由细胞因子介导的疾病,如关节炎。
  • ALPHA-KETOAMIDES AND DERIVATIVES THEREOF
    申请人:Boman Erik
    公开号:US20100273797A1
    公开(公告)日:2010-10-28
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as arthritis.
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别地,本发明的化合物可用作抗炎剂。还提供了制备这些药剂的方法,并将其用于预防或治疗由细胞因子介导的疾病,例如关节炎。
  • [EN] CYTOKINE INHIBITORS<br/>[FR] INHIBITEURS DES CYTOKINES
    申请人:KEMIA INC
    公开号:WO2005023761A3
    公开(公告)日:2005-07-14
  • Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site
    作者:Antonio Garrido Montalban、Erik Boman、Chau-Dung Chang、Susana Conde Ceide、Russell Dahl、David Dalesandro、Nancy G.J. Delaet、Eric Erb、Justin T. Ernst、Andrew Gibbs、Jeffrey Kahl、Linda Kessler、Jeff Kucharski、Christopher Lum、Jan Lundström、Stephen Miller、Hiroshi Nakanishi、Edward Roberts、Eddine Saiah、Robert Sullivan、Jan Urban、Zhijun Wang、Christopher J. Larson
    DOI:10.1016/j.bmcl.2010.06.102
    日期:2010.8
    We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多